About Noel Pharma (India) Private Limited
Data last updated: 06 January 2026
Noel Pharma (India) Private Limited is a private limited company based in Hyderabad, Telangana, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 15 November 2012, the company has been in operation for over 14 years.
Registered with ROC Hyderabad under CIN U24100TG2012PTC084182.
Capital: an authorised share capital of ₹5 Cr and a paid-up capital of ₹5 Cr. Formerly known as Noel Pharma (India) Private Limited and Noel Pharma (India) Limited. It is led by directors Venkataiah Sandrapalle and Sujatha Sandrapalle.
Last AGM: 30 September 2023. Financial statements filed for year ended 31 March 2023. Office: 24 – 85/7 Laxminarayana Nagar Colony New Ida Uppal, Hyderabad, Telangana, India – 500039.
As per the financials filed for FY 2023, the company reported a revenue of ₹2,410, a decline of 100% compared to the previous year.
The company has a workforce of approximately 13 employees as per the latest available data.
The company is associated with 1 brand - Noel Pharma. As per MCA filings, the company has open charges of ₹43.08 Cr on record.
The current compliance status is marked as active non-compliant by the Registrar of Companies. For more details, the company can be reached via its website noelpharma.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered Address24 – 85/7 Laxminarayana Nagar Colony New Ida Uppal, Hyderabad, Telangana, India – 500039
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Name History of Noel Pharma (India) Private Limited
Noel Pharma (India) Private Limited has undergone 2 name changes throughout its history. The company was previously known as Noel Pharma (India) Private Limited, and Noel Pharma (India) Limited. The current legal name is Noel Pharma (India) Private Limited, reflecting the company's evolution and rebranding over time.
| Company Name | Status |
|---|---|
| Noel Pharma (India) Private Limited | Current |
| Noel Pharma (India) Limited | Previous |
CIN History of Noel Pharma (India) Private Limited
Noel Pharma (India) Private Limited has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is U24100TG2012PTC084182, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24100TG2012PTC084182 | Current |
| U24100AP2012PTC084182 | Previous |
| U24100TG2012PLC084182 | Previous |
Associated Brands with Noel Pharma (India) Private Limited
Noel Pharma (India) Private Limited operates one associated brand: Noel pharma. These brands represent Noel Pharma (India) Private Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Manufacturer of branded and OTC products | noelpharma.com |
Auditor Details of Noel Pharma (India) Private Limited
Noel Pharma (India) Private Limited is audited by G P RAO & ASSOCIATES for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| G P RAO & ASSOCIATES | blur-value | blur-value | blur-value |
Board of Directors of Noel Pharma (India) Private Limited
Noel Pharma (India) Private Limited is currently managed by 2 directors, with 5 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Venkataiah Sandrapalle | Managing Director | 15 Nov 2012 | 13 Years 7 Months | Current |
| Sujatha Sandrapalle | Additional Director | 22 Jun 2018 | 8 Years 0 Months | Current |
Financials of Noel Pharma (India) Private Limited FY 2023 filings available
Noel Pharma (India) Private Limited reported revenue of ₹2,410 (down 100% YoY) for FY 2023. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Noel Pharma (India) Private Limited
As of FY 2023, Noel Pharma (India) Private Limited's shareholding pattern shows 100.00% by promoters. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Charges & Borrowings of Noel Pharma (India) Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 06 Apr 2013 | Electronica Finance Limited | ₹18.75 Lakh | Open |
| 06 Dec 2012 | State Bank of India | ₹42.89 Cr | Open |
Total charge records: 2 View all charges
Employees and EPFO Compliance at Noel Pharma (India) Private Limited
Noel Pharma (India) Private Limited has a workforce of 13 employees as of Mar 31, 2024.
Employee Count & EPFO Data of Noel Pharma (India) Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Noel Pharma (India) Private Limited
GSTIN & GST Filing Data of Noel Pharma (India) Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Noel Pharma (India) Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Noel Pharma (India) Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Noel Pharma (India) Private Limited
MSME Payment Delays by Noel Pharma (India) Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Noel Pharma (India) Private Limited
Subsidiaries & Group Companies of Noel Pharma (India) Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Noel Pharma (India) Private Limited with ownership details.
MCA Filings & Documents of Noel Pharma (India) Private Limited
MCA Filings & Documents of Noel Pharma (India) Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Noel Pharma (India) Private Limited
Frequently Asked Questions about Noel Pharma (India) Private Limited
Noel Pharma (India) Private Limited is an active private limited company in the pharma sector based in Hyderabad, Telangana, India. It was incorporated on 15 November 2012 (14+ years old) and is registered under CIN U24100TG2012PTC084182. The company has 13 employees.
Noel Pharma (India) Private Limited reported revenue of ₹2,410 for FY 2023 (down 100.00% YoY).
The current directors of Noel Pharma (India) Private Limited are:
The primary industry of Noel Pharma (India) Private Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Noel Pharma (India) Private Limited can be reached at the registered office: 24 – 857 Laxminarayana Nagar Colony New Ida Uppal, Hyderabad, Telangana, India – 500039, or through the website noelpharma.com.
The authorised capital is ₹5 Cr, and the paid-up capital is ₹5 Cr.